Neuronetics, Inc. (STIM) Stock Analysis and Metrics

Neuronetics

NASDAQ: STIM

$1.74 ▼ -0.14 (-7.71%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap130.83 Mn

P/E-2.72

P/S0.86

Div. Yield0.00

Total Debt (Qtr)61.55 Mn

Revenue Growth (1y) (Qtr)7.75

Add ratio to table…

About

Neuronetics, Inc. is a global leader in neuroscience that provides transcranial magnetic stimulation (TMS) therapies for patients with mental health disorders. Its flagship product the NeuroStar Advanced Therapy System is FDA cleared to treat major depressive disorder obsessive compulsive disorder adolescent major depressive disorder and anxious depression and the company operates Greenbrook treatment centers that deliver NeuroStar therapy and SPRAVATO esketamine nasal spray.

The company generates revenue from the sale of NeuroStar systems (capital equipment) recurring treatment sessions service and repair and extended warranty contracts. It also earns revenue from Greenbrook clinics that provide treatment sessions and SPRAVATO to patients. The majority of revenue comes from clinic and recurring treatment sessions. For the year ended December 31 2025 total revenue was $149.2 million.

The company operates through the following segments.

• NeuroStar: This segment encompasses the development manufacturing and sale of the NeuroStar Advanced Therapy System including capital equipment sales recurring treatment sessions service and repair and extended warranty contracts.

• Greenbrook: This segment operates a network of company owned treatment centers that deliver NeuroStar TMS therapy and SPRAVATO esketamine nasal spray to patients with major depressive disorder and related conditions.

Neuronetics holds a leading position in the TMS therapy market based on the number of patients treated and the size of its clinical data set. The NeuroStar Advanced Therapy System has received FDA clearances for multiple indications and is supported by reimbursement policies from over one hundred major private insurers and federal healthcare programs. Key competitors include Brainsway Apollo TMS Magstim MagVenture CloudTMS and Nexstim but Neuronetics differentiates itself through its extensive clinical evidence practice development resources and cloud based practice management platform. The acquisition of Greenbrook adds a treatment center network that operates with vertical integration and enhances customer access while providing recurring revenue streams.

The company’s primary customers are psychiatrists with additional sales to primary care physicians and pain management specialists. Greenbrook serves patients seeking outpatient mental health treatment at its network of treatment centers. Neuronetics targets approximately 53,000 psychiatrists across 26,000 psychiatric practices in the United States. Through its direct sales force and clinic operations the company works directly with healthcare providers and patients to deliver its TMS and SPRAVATO therapies.

Investment Thesis

▲ Bull case

Neuronetics (STIM) has significant upside potential from its underappreciated Greenbrook clinic network's ability to rapidly scale high-margin SPRAVATO treatment volumes, which grew double digits year-over-year in Q1 FY26 and benefit from a proven infrastructure that positions the company uniquely to capitalize on emerging psychedelic therapies like COMPASS Pathways' psilocybin treatment. The company's existing back-office capabilities for benefits investigation, prior authorization, and certified clinical settings—already validated through SPRAVATO rollout—create a durable competitive moat that would allow Greenbrook to capture disproportionate market share if psilocybin gains FDA approval, with management noting they are "among a very small number of providers genuinely equipped to deliver it," suggesting a first-mover advantage in a nascent but transformative mental health modality. The NeuroStar business is poised for reacceleration through strategic commercial model innovation, as CEO Daniel Reuvers explicitly highlighted pilots underway to expand go-to-market flexibility beyond traditional high-touch support, acknowledging that "not all customer's needs are the same" and that broadening the menu could unlock demand from price-sensitive or efficiency-focused segments currently underserved. This approach, combined with early positive feedback and plans to align incentive compensation with new models, addresses a critical historical constraint—over-reliance on a one-size-fits-all service model—that has likely suppressed NeuroStar's growth relative to its total addressable market, with system shipments already up 10% year-over-year in Q1 FY26 indicating underlying demand resilience. Operational turnaround initiatives at Neuronetics (STIM) are delivering tangible efficiency gains that are underappreciated by the market, including annualized savings of $2.5 million to $3 million from SG&A reductions beginning in Q3 FY26 and improved cash flow dynamics, with Q1 operating cash use improving by $7.6 million year-over-year to $9.4 million despite only modest revenue growth. The company's shift to leveling marketing investment throughout the year—rather than front-loading—reflects a more disciplined, sustainable approach to clinic acquisition costs, while management's confidence in achieving flat to positive operating cash flow in the second half of FY26 suggests a clearer path to profitability than current guidance implies, especially given the low base of $19 million in cash and $13 million unrestricted as of March 31, 2026.

Neuronetics (STIM) has significant upside potential from its underappreciated Greenbrook clinic network's ability to rapidly scale high-margin SPRAVATO treatment volumes, which grew double digits year-over-year in Q1 FY26 and benefit from a proven infrastructure that positions the company uniquely to capitalize on emerging psychedelic therapies like COMPASS Pathways' psilocybin treatment. The company's existing back-office capabilities for benefits investigation, prior authorization, and certified clinical settings—already validated through SPRAVATO rollout—create a durable competitive moat that would allow Greenbrook to capture disproportionate market share if psilocybin gains FDA approval, with management noting they are "among a very small number of providers genuinely equipped to deliver it," suggesting a first-mover advantage in a nascent but transformative mental health modality. The NeuroStar business is poised for reacceleration through strategic commercial model innovation, as CEO Daniel Reuvers explicitly highlighted pilots underway to expand go-to-market flexibility beyond traditional high-touch support, acknowledging that "not all customer's needs are the same" and that broadening the menu could unlock demand from price-sensitive or efficiency-focused segments currently underserved. This approach, combined with early positive feedback and plans to align incentive compensation with new models, addresses a critical historical constraint—over-reliance on a one-size-fits-all service model—that has likely suppressed NeuroStar's growth relative to its total addressable market, with system shipments already up 10% year-over-year in Q1 FY26 indicating underlying demand resilience. Operational turnaround initiatives at Neuronetics (STIM) are delivering tangible efficiency gains that are underappreciated by the market, including annualized savings of $2.5 million to $3 million from SG&A reductions beginning in Q3 FY26 and improved cash flow dynamics, with Q1 operating cash use improving by $7.6 million year-over-year to $9.4 million despite only modest revenue growth. The company's shift to leveling marketing investment throughout the year—rather than front-loading—reflects a more disciplined, sustainable approach to clinic acquisition costs, while management's confidence in achieving flat to positive operating cash flow in the second half of FY26 suggests a clearer path to profitability than current guidance implies, especially given the low base of $19 million in cash and $13 million unrestricted as of March 31, 2026.

▼ Bear case

Neuronetics (STIM) faces persistent structural headwinds in its core NeuroStar business, where total revenue declined 3% year-over-year in Q1 FY26 despite a 13% increase in U.S. system revenue, revealing a troubling divergence between hardware sales and treatment utilization that management attributed to customers working through excess inventory—a sign of channel stuffing or weakening end-demand that could recur if clinics remain reluctant to commit to ongoing consumable purchases after initial system placements, undermining the recurring revenue model essential for long-term NeuroStar profitability. The Greenbrook clinic segment's growth is overly dependent on SPRAVATO, which while growing double digits, introduces significant margin dilution and operational complexity through the buy-and-bill model, as evidenced by the decline in consolidated gross margin to 46.9% in Q1 FY26 from 49.2% in the prior year—a direct result of clinic revenues representing a higher revenue mix and the negative impact of scaling SPRAVATO buy-and-bill, suggesting that the company may be trading top-line growth for deteriorating unit economics, especially if reimbursement pressures intensify or if SPRAVATO growth fails to offset persistent weakness in TMS volumes within clinics, which were modestly below prior year levels due to weather disruption and lumpy ad spend. Neuronetics (STIM)'s liquidity position remains precarious despite recent improvements, with only $19 million in total cash and $13 million unrestricted as of March 31, 2026, and management's own guidance projecting operating cash flow between negative $13 million and negative $17 million for the full year FY26, implying a cash burn that could deplete reserves by year-end even under optimistic scenarios; this is exacerbated by the CFO departure creating leadership uncertainty during a critical turnaround phase, and while debt relief from Perceptive Advisors reduced interest expense, the one-time $5 million principal payment further strained near-term liquidity, leaving minimal buffer for execution missteps or delayed cash flow improvement in the second half of the year.

Neuronetics (STIM) faces persistent structural headwinds in its core NeuroStar business, where total revenue declined 3% year-over-year in Q1 FY26 despite a 13% increase in U.S. system revenue, revealing a troubling divergence between hardware sales and treatment utilization that management attributed to customers working through excess inventory—a sign of channel stuffing or weakening end-demand that could recur if clinics remain reluctant to commit to ongoing consumable purchases after initial system placements, undermining the recurring revenue model essential for long-term NeuroStar profitability. The Greenbrook clinic segment's growth is overly dependent on SPRAVATO, which while growing double digits, introduces significant margin dilution and operational complexity through the buy-and-bill model, as evidenced by the decline in consolidated gross margin to 46.9% in Q1 FY26 from 49.2% in the prior year—a direct result of clinic revenues representing a higher revenue mix and the negative impact of scaling SPRAVATO buy-and-bill, suggesting that the company may be trading top-line growth for deteriorating unit economics, especially if reimbursement pressures intensify or if SPRAVATO growth fails to offset persistent weakness in TMS volumes within clinics, which were modestly below prior year levels due to weather disruption and lumpy ad spend. Neuronetics (STIM)'s liquidity position remains precarious despite recent improvements, with only $19 million in total cash and $13 million unrestricted as of March 31, 2026, and management's own guidance projecting operating cash flow between negative $13 million and negative $17 million for the full year FY26, implying a cash burn that could deplete reserves by year-end even under optimistic scenarios; this is exacerbated by the CFO departure creating leadership uncertainty during a critical turnaround phase, and while debt relief from Perceptive Advisors reduced interest expense, the one-time $5 million principal payment further strained near-term liquidity, leaving minimal buffer for execution missteps or delayed cash flow improvement in the second half of the year.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password